Vascepa now Holds the Key to the Direction Amarin Could be Headed in
Navi Mumbai, Maharashtra -- (SBWIRE) -- 09/17/2013 -- Dublin, Ireland-based Amarin Corporation plc suffered a setback recently with a U.S. court allowing Teva Pharmaceuticals and TPG-owned Par Pharmaceutical to produce generic versions of GSK’s cholesterol medication Lovaza in the U.S. This news saw the stock taking a downward plunge.
While Amarin positions Vascepa as having no side effects as compared to Lovaza, it has reported positive results from various Vascepa-treated subjects. Data Presented at the annual scientific session of the National Lipid Association showed that Vascepa resulted in a reduction in lipoprotein particle concentration in Vascepa-treated subjects in the ANCHOR study.
During his presentation at the Jefferies 2013 Global Healthcare Conference, Amarin’s President, John Thero drew a differentiation between Lovaza and Vascepa, by stating that “Lovaza is a mixture, complex mixture of DHA and EPA and a bunch of other stuff whereas you can see that the Vascepa product is essentially one active ingredient which is the EPA side of things”.
In addition, Amarin has also secured additional formulary access for Vascepa with over 190 million lives now being covered by payers without restrictions including earlier than expected Tier 2 coverage totalling over 72 million lives. At the Q2 earnings call this August, CEO Joe Zakrzewski highlighted the fact that the number of clinicians prescribing Vascepa has more than doubled since the end of Q1 to over 9000 clinicians today. He went to state that “Vascepa is well positioned based on its efficacy, and safety profile including significant reduction in triglyceride, and a host of other lipid markers without increasing LDL-C, a claim that can't be made by our competition whether it be Lovaza or fenofibrate”.
Though Teva and Par could end up making inroads into Lovaza-territory, Amarin can be rest assured in Vascepa’s potential in the cholesterol medication space.
For the latest updates on Vascepa and Amarin’s plans with it going forward, read through John Thero’s presentation at the recent Canaccord Genuity Growth Conference, the link to which can be found here.
Earnings Impact Launches Ideaz
Ideaz are a collection of articles on currently trending stocks and topics which are making headlines. Certain articles provide you a graphical perspective of reasons behind why a company or its product stays in the news.
Earnings Impact Launches Analyz Thiz
Analyz Thiz helps you understand the correlation between the time when a company’s conference call transcript is available and the effect it has on its stock price at that point in time.
About Editor’s Picks
The latest feature on Earnings Impact is Editor's Picks, where a selection of game-changing transcripts are listed which explain why those companies are in the news.
About Earnings Impact
Earningsimpact.com is the destination for Transcripts of events that could impact stocks and its stakeholders. Transcripts are posted on earningsimpact.com within 2 hours of the live event. Active investors and traders will get access to this vital information much before the market reacts.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)